Summary Box: Amylin sues partner Eli Lilly and Co.

Mon, 05/16/2011 - 7:17am
The Associated Press

THE COMPLAINT: Amylin Pharmaceuticals Inc. said Monday it filed a lawsuit against Eli Lilly and Co., accusing the larger drugmaker of breaking their commercialization deal for diabetes drugs by teaming with the German company Boehringer Ingelheim to develop and sell a competing product.

AMYLIN'S GOAL: San Diego-based Amylin plans to continue working with Lilly, but it wants to keep Lilly from using the same sales force to sell both its product and the Boehringer product linagliptin, which goes by the brand name Tradjenta.

LILLY'S RESPONSE: Indianapolis-based Lilly said the lawsuit is without merit, and it will vigorously defend itself.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.